Research-Peptide Enforcement in 2026: Dated Record
Updated September 5, 2026
Peptide Sciences, placed by industry estimates as the largest US research-peptide vendor, announced voluntary closure on March 6, 2026. On March 31, FDA signed seven warning letters, posted April 7, and on July 30 a federal court sentenced the two Paradigm Peptides defendants. Three matters, each dated and sourced below.
The record to September 5, 2026
The year so far: the market's largest vendor exiting on its own announcement, two multi-recipient warning-letter batches, a single letter in June that moved the class boundary, and the sentencing that closed a criminal case whose public chronology began with a March 2024 site shutdown. No event later than September 1 is verified in this index's sources as of the dateline above.
| Date | Event | Source |
|---|---|---|
| March 6, 2026 | Peptide Sciences announces voluntary closure and halts all order processing; the site goes offline shortly after. | peptidesexplorer.com; biostrataresearch.com |
| March 31, 2026 | FDA signs seven warning letters to research-peptide sellers in six states. | FDA letter pages; safemedicines.org |
| April 7, 2026 | The seven letters are posted to FDA's public warning-letters index. | safemedicines.org; policycanary.io |
| July 30, 2026 | Sentencing in the Paradigm Peptides case, U.S. District Court, South Bend (N.D. Indiana). | CBS News; court record |
| August 24, 2026 | FDA signs five warning letters to research-peptide sellers in a second multi-recipient batch. | FDA letter pages |
| September 1, 2026 | The five letters are posted to FDA's public warning-letters index. | FDA warning-letters index |
March 6: the Peptide Sciences closure
The closure was announced by the company itself, with no enforcement action against it in the verified record. Industry estimates had placed Peptide Sciences in a revenue class around $7.4 million per month, the largest US research-peptide vendor at the time — figures this index carries as attributed estimates. The closure notice contained one operative sentence for later readers: any further sales under the brand are fraudulent. Unaffiliated sites reusing the branding have appeared since, and that sentence is the documented basis on which this index records them as unaffiliated. The company gave no detailed explanation; observers cite the 2024–2026 FDA enforcement wave, GLP-1 litigation pressure, and import restrictions as context, which this index records as attribution rather than established cause. Full entry: Peptide Sciences shutdown.
March 31 and April 7: seven letters
The signed date and the public date differ by a week: letters dated March 31, posting on April 7. The recipients — Lovega LLC dba Pink Pony Peptides (721088), Mile High Compounds LLC (721600), PekCura Labs (721709), Prime Sciences (721805), Gram Peptides (721806), FormPour (722215), and Guangzhou Huli Technology dba Fantasy Face (722228) — span Florida, Colorado, Arizona, California, Michigan, and Illinois. FDA's stated position, quoted from the letters: despite research-use-only disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use." Two findings run through the batch: therapeutic-effect descriptions on product pages, and administration supplies offered in the same shopping cart. The letters also document coded product names — "GLP-1 SM" and "GLP-3 RT" are the documented examples, recorded at batch level rather than per entity — which the agency read as circumvention, not cover. Per-entity records are collected at the April 2026 batch record.
June 17: one letter, and the class boundary drops
FDA issued letter 729447 to Wholesale Peptide of Brooksville, Florida, following a May 2026 review of the firm's website. The two products cited — "Prostamax" and "Gonadorelin" — are not GLP-1-class, which places this letter outside the pattern of the two batches above. Alongside conventional therapeutic claims for the first product, the agency quoted the second product's page language in full: statements attributing findings to investigations and scientists, placed explicitly in experimental subjects
and in laboratory settings
, one of which volunteers that the research is in early stages
. That language names no condition, addresses no reader, and promises nothing, and it was cited as evidence of intended use as a human drug. The research-use-only and not for human consumption
statements are disposed of in a single footnote. The dedicated record is at Wholesale Peptide warning letter.
July 30: sentencing closes the Paradigm case
In the U.S. District Court at South Bend, Indiana, Matthew Kawa received 70 months' imprisonment, one year of supervised release, and a $5 million forfeiture; Jennifer Stechkober received 16 months. Both had pleaded guilty on December 10, 2025. The sentences end a matter that spans this timeline's full range — storefront offline in March 2024, pleas in December 2025, sentences in July 2026. The dedicated record is at Paradigm Peptides sentencing.
August 24 and September 1: five letters, eight disclaimers
FDA signed five letters to research-peptide sellers on August 24, following reviews of each firm's website in July 2026, and posted them on September 1. The recipients are NuScience Peptides LLC (733652), TXP Innovations LLC dba Tex Peptides (735067), Royal Peptides LLC (734884), Peak Performance Peptides (735127), and Peptide Partners LLC (735063). All five were signed by the same official as the March 31 batch and run the same statutory chain. Two features distinguish the batch. Between them the five firms used eight different research-use and human-use disclaimer phrasings, five of which are new to this index, and every one met the same sentence. And the product copy the agency quoted spans an unusually wide range: one firm's pages carry ordinary sales writing, while another's are hedged throughout and describe preclinical models, and both received the same letter. The dedicated record is at the August 2026 batch record.
Position in the sequence
This is the third year page of the record. The multi-year table is the enforcement chronology; every entity named here has an entry in the vendor index.
Sources
- Peptides Explorer, Peptide Sciences closure report. peptidesexplorer.com
- BioStrata Research, Peptide Sciences closure analysis. biostrataresearch.com
- FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
- FDA Warning Letter, Mile High Compounds LLC, 721600-03312026. fda.gov
- FDA Warning Letter, Gram Peptides, 721806-03312026. fda.gov
- FDA Warning Letters index (retrieves the PekCura Labs 721709, Prime Sciences 721805, FormPour 722215, and Guangzhou Huli Technology dba Fantasy Face 722228 letters by recipient name). fda.gov
- Partnership for Safe Medicines, PDF summary of the seven letters (posted April 7, 2026). safemedicines.org
- Policy Canary analysis of the March 31, 2026 letters. policycanary.io
- CBS News coverage of the Paradigm Peptides sentencing. cbsnews.com
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.